Michail Shipitsin
About Michail Shipitsin
Michail Shipitsin's Title in Biomarker Development
Michail Shipitsin holds a prominent position in the field of biomarker development. With over 15 years of dedicated expertise, Shipitsin has significantly contributed to both translational and clinical biomarker research and development.
Michail Shipitsin's Education and Expertise
Michail Shipitsin earned a Diploma in Molecular Biology from Novosibirsk State University. He further advanced his education with a Ph.D. in Biochemistry from Tufts University. His academic background is complemented by extensive research experience at the Dana-Farber Cancer Institute, where he focused on biomarkers in breast cancer.
Michail Shipitsin's Background in Biomarker Development
Shipitsin's professional journey includes pivotal roles in prominent biotechnology firms. He has served as the Director and Head of Biomarker Development at Metamark Genetics and XTuit Pharmaceuticals. His responsibilities involved leading and innovating in the field of biomarker tests and automated imaging techniques.
Michail Shipitsin's Achievements in Biomarker Research
Michail Shipitsin is recognized for his pioneering work in automated, digital multiplex imaging and clinical biomarker tests. Notably, he was the scientific lead behind ProMark®, the first-ever marketed, automated quantitative prognostic prostate cancer test. His contributions have had a significant impact on the field of diagnostic oncology.